EBS - Dosing underway in Emergent Bio's Phase 1 study of influenza vaccine candidate

Emergent BioSolutions (NYSE:EBS) announces the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of investigational universal influenza vaccine candidate. This current version of Emergent’s universal influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses. The dose-escalation study will evaluate the vaccine candidate at two dose levels and two schedules in 60 healthy adult individuals aged 18 to 45. This phase 1 study, being conducted in Australia, is fully funded by Emergent.

For further details see:

Dosing underway in Emergent Bio's Phase 1 study of influenza vaccine candidate